logo-loader
HealthPharma & Biotech
AstraZeneca

AstraZeneca scores another late-stage win, this time with COPD drug

Breztri Aerosphere, even when taken in smaller doses, was shown to be much more effective in reducing the number of exacerbations suffered by COPD patients than current drugs

AstraZeneca -
Astra has enjoyed successes in a number of studies of late

AstraZeneca PLC (LON:AZN) has scored another late-stage trial success, this time with its Breztri Aerosphere chronic obstructive pulmonary disease (COPD) drug.

The triple-combination drug demonstrated a “statistically-significant” reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies Bevespi Aerosphere and PT009.

READ: Astra’s remarkable drug pipeline turnaround continues

Even more impressively, patients only had to take half as much of Breztri Aerosphere to get better results.

“Exacerbations are devastating events for patients and can lead to a permanent loss of lung function,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.

“The phase III ETHOS trial builds on the phase III KRONOS data which together show Breztri Aerosphere's ability to reduce exacerbation risk in a broad range of patients with COPD, irrespective of whether they have had an exacerbation in the previous twelve months.”

Orphan drug status for Fasenra

In a separate statement, Astra confirmed its Fasenra drug has been granted orphan drug status by the US regulator as a treatment for eosinophilic esophagitis (EoE).

EoE is an allergic inflammatory disease of the oesophagus.

The Food and Drug Administration grants orphan status to drugs that are intended to treat diseases or disorders that affect fewer than 200,000 people in the US.

Because the market is so small, regulators offer companies developing such treatments a number of benefits, such as tax credits, reduced fees and a less onerous approval process.

Shares were up 0.8% to 7,298p.

Quick facts: AstraZeneca

Price: 6772 GBX

Market: LSE
Market Cap: £88.84 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 days, 15 hours ago

2 min read